Liver elastometry and alcohol withdrawal: Median-term follow-up in a psychiatric unit.


Journal

Alcohol (Fayetteville, N.Y.)
ISSN: 1873-6823
Titre abrégé: Alcohol
Pays: United States
ID NLM: 8502311

Informations de publication

Date de publication:
12 2020
Historique:
received: 13 09 2019
revised: 07 07 2020
accepted: 16 07 2020
pubmed: 28 7 2020
medline: 16 9 2021
entrez: 26 7 2020
Statut: ppublish

Résumé

The measurement of liver stiffness (LS) shows promise as a follow-up tool after alcohol withdrawal, but it has mainly been studied in the early phase or in patients with severe liver disease. A 6-month ancillary study of a specific psychiatric cohort of alcoholic patients without known liver disease followed after withdrawal was conducted (Clinical Trial NCT01491347). Clinical and biological data and LS values were collected every 2 months. A total of 129 patients were included in the study; 93 had an LS assessment within the first 7 days, and 37 had all four LS measurements. Only seven (7.5%) patients had an initial LS > 12.1 kPa, the threshold used to define severe fibrosis. Abstinence was not associated with changes in LS at the various median-term follow-up periods. However, LS of abstinent subjects decreased significantly relative to that of non-abstinent subjects between M0 and M2. CAP™ values were not associated with abstinence. The systematic median-term follow-up of withdrawn patients does not appear to be contributory. However, LS could help to detect relapse in the first 2 months after withdrawal for subjects treated in a psychiatric hospital for dependence. It thus could serve as a motivation tool. Prospective studies with various and higher baseline LS values are warranted for simultaneous longitudinal assessment, including for very short- and long-term LS after withdrawal.

Identifiants

pubmed: 32711035
pii: S0741-8329(20)30251-2
doi: 10.1016/j.alcohol.2020.07.007
pii:
doi:

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

49-56

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Paul Carrier (P)

Fédération d'Hépatologie, Service d'Hépato-gastroentérologie, Centre Hospitalier Universitaire Dupuytren, Avenue Martin Luther King, Limoges, 87025, France; INSERM Unité S-1248 Faculté de Médecine et de Pharmacie, Rue Docteur Marcland, Limoges, 87025, France; Pôle Universitaire d'Addictologie, Centre Hospitalier Esquirol, Rue du Docteur Marcland, Limoges, 87025, France.

Murielle Girard (M)

Unité de Recherche et de Neurostimulation, Centre Hospitalier Esquirol, Rue du Docteur Marcland, Limoges, 87025, France; INSERM UMR 1094/NET Faculté de Médecine et de Pharmacie, Rue Docteur Marcland, Limoges, France. Electronic address: murielle.girard@ch-esquirol-limoges.fr.

Marilyne Debette-Gratien (M)

Fédération d'Hépatologie, Service d'Hépato-gastroentérologie, Centre Hospitalier Universitaire Dupuytren, Avenue Martin Luther King, Limoges, 87025, France; INSERM Unité S-1248 Faculté de Médecine et de Pharmacie, Rue Docteur Marcland, Limoges, 87025, France; Pôle Universitaire d'Addictologie, Centre Hospitalier Esquirol, Rue du Docteur Marcland, Limoges, 87025, France.

Natacha Ouedraogo (N)

Pôle Universitaire d'Addictologie, Centre Hospitalier Esquirol, Rue du Docteur Marcland, Limoges, 87025, France.

Véronique Loustaud-Ratti (V)

Fédération d'Hépatologie, Service d'Hépato-gastroentérologie, Centre Hospitalier Universitaire Dupuytren, Avenue Martin Luther King, Limoges, 87025, France; INSERM Unité S-1248 Faculté de Médecine et de Pharmacie, Rue Docteur Marcland, Limoges, 87025, France.

Philippe Nubukpo (P)

Pôle Universitaire d'Addictologie, Centre Hospitalier Esquirol, Rue du Docteur Marcland, Limoges, 87025, France; Unité de Recherche et de Neurostimulation, Centre Hospitalier Esquirol, Rue du Docteur Marcland, Limoges, 87025, France; INSERM UMR 1094/NET Faculté de Médecine et de Pharmacie, Rue Docteur Marcland, Limoges, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH